| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia (NCT05320198) | Disc Medicine, Inc | 2022-06-06 |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) (NCT04551053) | Incyte Corporation | 2021-05-26 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) (NCT04551066) | Incyte Corporation | 2021-05-24 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (NCT04603495) | Novartis Pharmaceuticals | 2021-04-09 |
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia (NCT04896112) | Lynk Pharmaceuticals Co., Ltd | 2021-04-08 |
| INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders (NCT04455841) | Incyte Corporation | 2021-03-19 |
| Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (NCT04676529) | Syntara | 2021-02-18 |
| Study of Select Combinations in Adults With Myelofibrosis (NCT04283526) | Novartis Pharmaceuticals | 2020-11-30 |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) (NCT04173494) | Sierra Oncology LLC - a GSK company | 2020-02-07 |
| Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (NCT03627403) | University of Utah | 2019-05-10 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (NCT03755518) | Celgene | 2019-03-27 |
| MPN-RC 118 AVID200 in Myelofibrosis (NCT03895112) | John Mascarenhas | 2019-02-15 |
| Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis (NCT03373877) | Samus Therapeutics, Inc. | 2018-05-24 |
| Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib (NCT04884191) | CTI BioPharma | 2017-07-31 |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (NCT03165734) | Swedish Orphan Biovitrum | 2017-06-26 |
| PD-1 Inhibition in Advanced Myeloproliferative Neoplasms (NCT03065400) | John Mascarenhas | 2017-06-14 |
| Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (NCT02966353) | Novartis Pharmaceuticals | 2017-03-31 |
| Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia (NCT02124746) | Sierra Oncology LLC - a GSK company | 2014-04-30 |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (NCT02055781) | CTI BioPharma | 2014-02-01 |
| Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (NCT01969838) | Sierra Oncology LLC - a GSK company | 2013-12-06 |
| Ruxolitinib Prior to Transplant in Patients With Myelofibrosis (NCT01790295) | John Mascarenhas | 2013-11-01 |
| A Phase 2 Study of RO7490677 In Participants With Myelofibrosis (NCT01981850) | Hoffmann-La Roche | 2013-10-01 |
| Pacritinib Versus Best Available Therapy to Treat Myelofibrosis (NCT01773187) | CTI BioPharma | 2013-01-01 |
| A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis (NCT05044026) | Novartis Pharmaceuticals | 2012-09-20 |
| Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis (NCT01433445) | Novartis Pharmaceuticals | 2011-11-01 |
| Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis (NCT01445769) | Incyte Corporation | 2011-09-01 |
| Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (NCT01423058) | Sierra Oncology LLC - a GSK company | 2011-08-01 |
| Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) (NCT01236638) | Sierra Oncology LLC - a GSK company | 2010-11-01 |